相关实验视频

Updated: Jun 16, 2025

Segmentation and Linear Measurement for Body Composition Analysis using Slice-O-Matic and Horos

Segmentation and Linear Measurement for Body Composition Analysis using Slice-O-Matic and Horos

Published on: March 21, 2021

体质指数的多基因分数与细胞癌患者的死亡率相关

Zhengyi Deng¹, Rebecca E Graff², Ken Batai³

¹Department of Urology, Stanford University School of Medicine, Stanford, CA, USA. zdeng18@stanford.edu.

International journal of obesity (2005)

|August 16, 2024

概括

这项研究发现,较高体重指数 (BMI) 的遗传倾向与细胞癌 (RCC) 患者的死亡率之间没有联系. 结果表明逆因果关系可能解释肥胖和较低的RCC死亡率之间的先前关联.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
流行病学流行病学

背景情况:

体质指数 (BMI) 与细胞癌 (RCC) 患者的死亡率之间的关系是有争议的.
观察性研究表明,更高的BMI具有潜在的生存益处,但混和反向因果关系等方法限制可能会导致结果偏差.
利用与BMI相关的遗传变异提供了一种方法来缓解这些偏差,并获得更可靠的估计.

研究的目的:

为了研究更高BMI的遗传倾向和细胞癌 (RCC) 患者的死亡率之间的关联.
将这些遗传发现与测量BMI和腰部比率 (WHR) 观察到的关联进行比较,使用诊断前的人类测量数据.
评估逆因果关系对RCC中脂肪和死亡率之间观察到的关联的潜在影响.

主要方法:

进行了一项前性队列研究,涉及来自英国生物库的1264名RCC患者.
使用336个与BMI相关的遗传变异构建了一个BMI多基因分数 (PGS).
用后勤和考克斯回归来评估BMI PGS,测量诊断前BMI和WHR与全因和RCC特定死亡率之间的关联,分析按人体测量和诊断之间的时间间隔分层.

主要成果:

在RCC患者的BMI PGS和全因死亡率之间没有发现显著的关联 (HR每SD增加=0.98;95%CI:0.88,1.10).
同样,诊断前的BMI (HR每5kg/m2增加=0.93;95%CI:0.83,1.04) 和WHR (HR每0.1增加=0.97;95%CI:0.83,1.13) 也没有与死亡率相关.
在诊断前两年内测量的患者中,较高的BMI和WHR与较低的死亡率相关 (例如,BMIHR每5kg/m2=0.76;95%CI:0.59,0.98),这表明反向因果关系.

结论:

对较高BMI的遗传倾向和测量到的诊断前肥胖症与细胞癌患者的死亡率无关.
这些发现表明,反向因果关系可能解释了先前观察到的肥胖与RCC中死亡率降低之间的关联.
未来的研究应该仔细考虑混和反向因果关系,以产生对BMI和RCC结果之间的关系的公正估计.

更多相关视频

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

相关概念视频

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...